Non-invasive technique can help identify infants at high risk for retinopathy of prematurity

Research from Ann & Robert H. Lurie Children's Hospital of Chicago promises to spare many premature infants from undergoing invasive eye exams to detect retinopathy of prematurity (ROP), the most common cause of preventable lifelong blindness in children in the U.S.

ROP is caused by an abnormal development of small blood vessels on the retina. Isabelle De Plaen, MD, and colleagues found that imaging the capillaries in the nailbed of preemies within the first month of life using a non-invasive technique, called nailbed capillaroscopy, can identify infants at high risk for developing ROP. This screening could eliminate the need to evaluate all premature infants with eye exams about a month later. Findings were published in the Journal of Pediatrics.

Abnormal systemic vascular development starts much earlier than we thought. By measuring the nailbed capillary density soon after birth we can identify premature infants at higher risk for developing ROP long before it is detectable by an eye exam. Earlier identification of these infants reduces the need to subject all premature babies to highly invasive eye exams. Our findings might also lead to the development of earlier preventive or therapeutic interventions for ROP and other complications of prematurity associated with maldevelopment of microvasculature."

Dr. De Plaen, senior author and neonatologist at Lurie Children's, Professor of Pediatrics at Northwestern University Feinberg School of Medicine

ROP occurs in about 1/500-1/1,000 premature infants. It affects 33%-60% of babies with very low birth weight (less than 1,500g).

In the cohort of 32 premature neonates they studied, Dr. De Plaen and colleagues found that nailbed capillary density was higher in babies who later developed ROP. Microvascular density in the first month of life also correlated with the severity of ROP.

"The differences we found in microvascular density were most striking near birth, suggesting that perturbed microvascular development may begin in utero during the perinatal period, impacting organ microvascular development," said Dr. De Plaen. "We speculate that nailfold microvascular density quantification has the potential to help further characterize the link between the uterine environment, placental health and outcomes of preterm birth, so that we can improve those outcomes."

Research at Ann & Robert H. Lurie Children's Hospital of Chicago is conducted through Stanley Manne Children's Research Institute. The Manne Research Institute is focused on improving child health, transforming pediatric medicine and ensuring healthier futures through the relentless pursuit of knowledge. Lurie Children's is a nonprofit organization committed to providing access to exceptional care for every child. It is ranked as one of the nation's top children's hospitals by U.S. News & World Report. Lurie Children's is the pediatric training ground for Northwestern University Feinberg School of Medicine.

Source:
Journal reference:

York, D., et al. (2023) Nailfold Capillaroscopy: A Promising, Noninvasive Approach to Predict Retinopathy of Prematurity. The Journal of Pediatrics. doi.org/10.1016/j.jpeds.2023.113478.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17